[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS Financial Services on 09/04/2025 with an aggregate market value of $562,766. The shares were acquired the same day via equity compensation from Surgery Partners and were paid for by an equity option exercise. The filing also discloses that Wayne DeVeydt sold a total of 187,865 common shares in the prior three months for aggregate gross proceeds of $4,265,885 across five transactions dated 08/21/2025 through 09/03/2025. The filer affirms no undisclosed material adverse information.

Positive

• Detailed disclosure of broker, share counts, dates, and aggregate market value enhances transparency
• Acquisition and payment method are explicitly stated (equity compensation; equity option exercise), clarifying the transaction origin
• Recent insider sale totals ($4,265,885) are fully reported, aiding investor visibility into insider liquidity

Negative

• Substantial insider sales in the prior three months totaling 187,865 shares may be viewed unfavorably by some investors
• No filing date or signature date is provided in the visible content, limiting temporal context for the notice

Insights

Securities Analyst

TL;DR: Routine insider sale and option exercise disclosed; notable recent insider liquidity totaling $4.27M.

The Form 144 documents a planned sale of 25,000 common shares acquired and exercised on 09/04/2025, routed through UBS Financial Services. The filing is specific about timing, consideration (equity option exercise), and market value. Recent sales by Wayne DeVeydt total 187,865 shares generating $4,265,885 in gross proceeds over five trades in late August and early September 2025. This disclosure provides transparent information on insider liquidity but does not include any forward-looking statements or operational data about the issuer.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; filings confirm insider compliance and representations.

The submission contains required details: class of security, broker, number of shares, aggregate market value, acquisition source, and payment method. The signer represents absence of undisclosed material adverse information. The record of multiple recent sales and option exercise is relevant for governance transparency and monitoring insider trading practices, but the filing contains no allegations or governance failures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	25000	562766	128209410	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/04/2025	equity compensation	Surgery Partners, Inc.			25000	09/04/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Surgery Partners (SGRY) disclose?

The form discloses a proposed sale of 25,000 common shares via UBS on 09/04/2025 with aggregate market value $562,766, acquired via equity compensation and paid by an equity option exercise.

Who sold shares of SGRY in the past three months and how many?

Wayne DeVeydt sold a total of 187,865 common shares across five transactions dated 08/21/2025 to 09/03/2025.

How much gross proceeds were generated from recent insider sales?

The five disclosed sales by Wayne DeVeydt generated aggregate gross proceeds of $4,265,885.

How were the 25,000 shares being sold acquired?

They were acquired on 09/04/2025 as equity compensation from Surgery Partners, Inc., with payment via an equity option exercise.

Through which broker will the proposed sale occur?

The proposed sale is to be executed through UBS Financial Services Inc, 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ.